Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZYCWT)

Drug Name
BCI-632 Drug Info
Synonyms
LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Major depressive disorder 6A70.3 Phase 1 [1]
Cross-matching ID
PubChem CID
9886034
CAS Number
CAS 569686-87-9
TTD Drug ID
DMZYCWT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Metabotropic glutamate receptor 3 (mGluR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY404039 DMWZIRJ Schizophrenia 6A20 Phase 3 [3]
RO-4995819 DMNTC7O Major depressive disorder 6A70.3 Phase 2 [4]
Oleoyl-estrone DM0RA8F Alzheimer disease 8A20 Phase 2 [5]
MP-101 DMYCITZ Alzheimer disease 8A20 Phase 2 [6]
BCI-838 DMRXDN3 Major depressive disorder 6A70.3 Phase 1 [7]
Pomaglumetad DMTOLI5 Schizophrenia 6A20 Phase 1 [8]
PMID25435285-Compound-16 DMKFX2G N. A. N. A. Patented [9]
PMID25435285-Compound-15 DMHBWNS N. A. N. A. Patented [9]
PMID25435285-Compound-20 DMG9FYH N. A. N. A. Patented [9]
PMID25435285-Compound-22 DM27U1F N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Metabotropic glutamate receptor 2 (mGluR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RO-4995819 DMNTC7O Major depressive disorder 6A70.3 Phase 2 [4]
Oleoyl-estrone DM0RA8F Alzheimer disease 8A20 Phase 2 [5]
MP-101 DMYCITZ Alzheimer disease 8A20 Phase 2 [6]
JNJ-64281802 DMNMSVX Dengue 1D20-1D2Z Phase 2 [10]
BCI-838 DMRXDN3 Major depressive disorder 6A70.3 Phase 1 [7]
Pomaglumetad DMTOLI5 Schizophrenia 6A20 Phase 1 [8]
LY-2979165 DM16IX2 Bipolar disorder 6A60 Phase 1 [11]
JNJ-42491293 DMOL9JR Psychiatric disorder 6E8Z Phase 1 [12]
ADX71149 DMBUOX4 Epilepsy 8A60-8A68 Phase 1 [13]
PMID25435285-Compound-16 DMKFX2G N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 2 (mGluR2) TTXJ47W GRM2_HUMAN Antagonist [2]
Metabotropic glutamate receptor 3 (mGluR3) TT8A9EF GRM3_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01548703) A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers. U.S. National Institutes of Health.
2 Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
3 Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
4 Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
7 Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
8 LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
9 Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
10 Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J Psychopharmacol. 2015 Apr;29(4):414-25.
11 Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
12 Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708.
13 MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).